Skip to main navigation
Skip to search
Skip to main content
UNT Health Home
Search content at UNT Health
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Anti-leukemic response of a NSAID, tolfenamic acid
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Anti-leukemic response of a NSAID, tolfenamic acid'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
100%
Tolfenamic Acid
100%
Antileukemic Activity
100%
Cell Viability
15%
Survivin
15%
G1 Arrest
15%
Apoptosis
7%
Transcription Factor
7%
Leukemia
7%
Western Blot
7%
Novel Therapeutics
7%
Flow Cytometry
7%
Mouse Tumor
7%
Tumor Growth
7%
Acid Treatment
7%
Cancer Model
7%
Specificity Protein 1
7%
Cancer Cells
7%
Phase-type Distribution
7%
Cell Cycle Phases
7%
Apoptosis Induction
7%
Annexin V
7%
Target Specificity
7%
Cell Tumor
7%
Jurkat
7%
Inhibitor of Apoptosis Proteins
7%
Survivin Expression
7%
Life Cycle Analysis
7%
Acid Activation
7%
Time Response
7%
Nalm-6 Cells
7%
Preclinical Experiment
7%
Dose-dependent Response
7%
Cleaved PARP
7%
Distributional Analysis
7%
Caspase 3/7
7%
Immunology and Microbiology
Programmed Cell Death
100%
Cell Cycle
66%
Cell Viability
66%
Cell Line
33%
Transcription Factors
33%
Western Blot
33%
Protein Family
33%
Cancer Cell
33%
Caspase
33%
G1 Phase Cell Cycle Checkpoint
33%
Cell Cycle Phase
33%
Pharmacology, Toxicology and Pharmaceutical Science
Non-Steroidal Anti-Inflammatory Drug
100%
Tolfenamic Acid
100%
Survivin
23%
Malignant Neoplasm
15%
Cell Viability
15%
Transcription Factors
7%
Tumor Growth
7%
Western Blot
7%
Flow Cytometry
7%
Leukemia
7%
Cancer Model
7%
Lipocortin 5
7%
Caspase 3
7%
Inhibitor of Apoptosis Protein
7%
Cell-Cycle Analysis
7%